Intravenous colistin use for multidrug-resistant gram-negative infections in pediatric patients

Balkan Medical Journal

Volumn 33, Issue 6, 2016, Pages 627-632

  Karaaslan, Ayşe ^a   Çağan, Eren ^a   Kadayifci, Eda Kepenekli ^a   Atıcı, Serkan ^a   Akkoç, Gülşen ^a   Yakut, Nurhayat ^a   Demir, Sevliya Öcal ^a   Soysal, Ahmet ^a   Bakır, Mustafa ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Children; Colistin; Multidrug resistant gram negative infections

Indexed keywords

CARBAPENEM; COLISTIN; QUINOLONE; RIFAMPICIN; SULTAMICILLIN;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; ARTICLE; ATAXIA; BACTEREMIA; CHILD; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISTAL PARESTHESIA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER CLOACAE; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; NEPHROTOXICITY; NEUROTOXICITY; PEDIATRICS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEIZURE; SEPSIS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT DURATION; TURKEY (REPUBLIC); URINARY TRACT INFECTION; VERTIGO; WOUND INFECTION;

EID: 84998717730     PISSN: 21463123     EISSN: 21463131     Source Type: Journal    
DOI: 10.5152/balkanmedj.2016.16210     Document Type: Article

References (28)

1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81. [CrossRef]
2. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-81. [CrossRef]
3. Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected Gram-negative sepsis. JAMA 1995; 274: 338-45. [CrossRef]
4. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem- hydrolyzing enzymes. Future Microbiol 2011; 6: 653-66. [CrossRef]
5. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41. [CrossRef]
6. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1: 14. [CrossRef]
7. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18: 18-29. [CrossRef]
8. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-40. Erratum in: Am J Infect Control 1988; 16: 177. [CrossRef]
9. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008; 46: 1121-2. [CrossRef]
10. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrugresistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601. [CrossRef]
11. X-Gen Pharmaceuticals Inc. Colistimethate for injection, USP: for intramuscular and intravenous use. [Accessed April 9, 2010]; Available from: http://x-gen.us/wp-content/uploads/2014/03/ Colistimethate_pi.pdf
12. European Medicines Agency completes review of polymyxinbased medicines. (Published in 24/10/2014); Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Press_release/2014/10/WC500176334.pdf
13. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (Colistin) use in critically Ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28: 123-7. [CrossRef]
14. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35: 297-300. [CrossRef]
15. Karbuz A, Özdemir H, Yaman A, Kocabaş BA, Ödek C, Güriz H, et al. The use of colistin in critically Ill children in a pediatric intensive care unit. Pediatr Infect Dis J 2014; 33: 19-24. [CrossRef]
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement M100-S21. Wayne, PA, USA: CLSI; 2011.
17. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical MIC breakpoints. Available from: http://www.eucast.org/clinical_breakpoints.
18. Furtado GH, d’Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30: 315-9. [CrossRef]
19. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009; 33: 503. [CrossRef]
20. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003; 47: 2659-62. [CrossRef]
21. Nation RL, Li J. Polymyxins. In: The Use of Antibiotics, Kucers A. editor. London: Heinemann; 2010: 955. [CrossRef]
22. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6. [CrossRef]
23. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54: 1720-6. [CrossRef]
24. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-8. [CrossRef]
25. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5: 1. [CrossRef]
26. Ziad Daoud, Najwa Mansour, Khalil Masri. Synergistic Combination of Carbapenems and Colistin against P. aeruginosa and A. baumannii. J Med Microbiol 2013; 3: 253-8. [CrossRef]
27. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (Colistin) use in critically Ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28: 123-7. [CrossRef]
28. Kapoor K, Jajoo M, Dublish S, Dabas V, Gupta S, Manchanda V. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients. Pediatr Crit Care Med 2013; 14: 268-72. [CrossRef]